Anti-Human CD19 Recombinant Antibody (cHD37) (CAT#: TAB-1621CL)

Figure 1 Time-dependent ADCC against Daudi target cells using human NK effector cells at a 50:1 E/T ratio.

White bars, 6-hr lysis; black bars, 18-hr lysis. The % specific lysis mediated by cHD37 at 6 hr versus 18 hr is significantly different (p < 0.015). The % specific lysis mediated by cHD37-DcVV at 6 hr versus 18 hr is significantly different (p < 0.047). The % specific lysis mediated by cHD37-DcVV versus cHD37 at 6 hr is significantly different (p < 0.0005). The % specific lysis mediated by cHD37-DcVV versus cHD37 at 18 hr is significantly different (p < 0.01). The figure depicts the average of three separate experiments each carried out in triplicate ± SD.

Liu, X. Y., Pop, L. M., Tsai, L., Pop, I. V., & Vitetta, E. S. (2011). Chimeric, divalent and tetravalent anti‐CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B‐cell lymphoma and pre‐B acute lymphoblastic leukemia cell lines. International journal of cancer, 129(2), 497-506.

Figure 2 Efficacy of HD37 MAbs in SCID mice xenografted with either NALM-6 (a) or Daudi (b) Cells.

(a) SCID/NALM-6 mice treated on days 1 through 4 after tumor inoculation with (●) PBS, (■) 7.5 μg/g MOPC-21, (▲) 7.5 μg/g HD37, (▼) 7.5 μg/g cHD37 and (♦) 10 μg/g cHD37-DcVV. (b) SCID/Daudi mice treated on days 1 through 4 post-tumor inoculation with (●) PBS, (▼) 1.9 μg/g cHD37, (▲) 3.8 μg/g cHD37, (■) 7.5 μg/g cHD37, (○) 2.5 μg/g cHD37-DcVV, (□) 5 μg/g cHD37-DcVV and (♦) 10 μg/g cHD37-DcVV. Groups of five mice were treated as described in the text. The graphs depict one representative experiment of three.

Liu, X. Y., Pop, L. M., Tsai, L., Pop, I. V., & Vitetta, E. S. (2011). Chimeric, divalent and tetravalent anti‐CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B‐cell lymphoma and pre‐B acute lymphoblastic leukemia cell lines. International journal of cancer, 129(2), 497-506.